Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GPR6 | P46095 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2866934 | 1.00 | ALDH1A1 (0.42) | ALDH1A1NPSR1CNR2NPC1RAB9A | |
| SCHEMBL2862523 | 0.91 | ALDH1A1 (0.41) | ALDH1A1NPSR1CNR2NPC1RAB9A | |
| SCHEMBL2862528 | 0.91 | ALDH1A1 (0.41) | ALDH1A1NPSR1CNR2NPC1RAB9A | |
| SCHEMBL2869359 | 0.89 | ALDH1A1 (0.44) | ALDH1A1NPSR1CNR2NPC1RAB9A | |
| SCHEMBL2869355 | 0.89 | ALDH1A1 (0.44) | ALDH1A1NPSR1CNR2NPC1RAB9A | |
| SCHEMBL2869913 | 0.86 | ALDH1A1 (0.42) | ALDH1A1NPSR1CNR2NPC1RAB9A | |
| SCHEMBL2869911 | 0.86 | ALDH1A1 (0.42) | ALDH1A1NPSR1CNR2NPC1RAB9A | |
| SCHEMBL2864719 | 0.86 | ALDH1A1 (0.45) | ALDH1A1NPSR1CNR2NPC1RAB9A | |
| SCHEMBL2864716 | 0.86 | ALDH1A1 (0.45) | ALDH1A1NPSR1CNR2NPC1RAB9A | |
| SCHEMBL2857836 | 0.86 | ALDH1A1 (0.44) | ALDH1A1NPSR1CNR2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109640941-B | Odorless and highly stable cosmetic composition | 株式会社爱茉莉太平洋 | 2022-04-22 | — | — | CN | claimed |
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | claimed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | claimed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | claimed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | claimed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | claimed |
| CN-107134556-B | Lithium ion battery diaphragm | 乐凯胶片股份有限公司 | 2020-05-15 | — | — | CN | disclosed |
| CN-110198982-A | Peroxide modified polyethylene, composition and application | 伊奎斯塔化学有限公司 | 2019-09-03 | — | — | CN | disclosed |
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8383657-B2 | Thiazolylidine urea and amide derivatives and methods of use thereof | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100249138-A1 | MPZP: A SMALL MOLECULE CORTICOTROPIN-RELEASING FACTOR TYPE 1 RECEPTOR (CRF1) ANTOGONIST | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-09-30 | — | — | US | disclosed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2009036340-A2 | MPZP: A SMALL MOLECULE CORTICOTROPIN-RELEASING FACTOR TYPE 1 RECEPTOR (CRF1) ANTAGONIST | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | NMUR1, NMUR2, PAM | ALDH1A1 2649/4885NPSR1 192/4885CNR2 156/4885 |
| US-20100249138-A1 | MPZP: A SMALL MOLECULE CORTICOTROPIN-RELEASING FACTOR TYPE 1 RECEPTOR (CRF1) ANTOGONIST | CRHR1, CRH, CRHR2 | ALDH1A1 1562/4885NPSR1 19/4885CNR2 116/4885 |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | CHRNA4, CHRNA5, CHRNA3 | ALDH1A1 2032/4885NPSR1 153/4885CNR2 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.